Pharma Solutions

  • Recognised multiple times at world-class forums for good performance in quality, reliability and compliance
  • Successfully integrated Coldstream acquisition - currently investing in its capability & capacity expansion
  • Capacity expansion at Discovery Services and Grangemouth completed

Critical Care

  • Significantly improved Sevoflurane market share in UK (42%) and Japan (56%)
  • Launched co-promotion of two of Cumberland’s branded hospital products in the United States

Consumer Products

  • Acquired “Little’s” - a baby care brand portfolio
  • Acquired five brands from Organon India & MSD - Include leading brands like Naturolax, Lactobacil & Farizym
  • Entered an agreement to acquire four brands from Pfizer Ltd in May 2016
  • Expanded distribution network to 1,500 towns from 481 towns till last year

Financial Services

  • Loan Book grew by 174% to ₹13,048 Crores as on 31 Mar 2016 vs. ₹4,766 Crores as on 31 Mar 2015
  • Entry into Construction Finance enabled significant scale up in the loan book - Now 42% of the Real Estate loan book
  • Entered construction finance for commercial projects as well
  • Special Situations loan book grew to ₹1,515 Crores as on 31 Mar 2016 vs. ₹425 Crores as on 31 Mar 2015
  • Among best-in-class NPA performance
  • Alternative AUM was up at ₹8,717 Crores

Information Management

  • Entry in payer market through acquisition of Adaptive Software
  • Entry in provider market through acquisition of HBI
  • Opened two offices in India - On target with 160+ positions on boarded




growth in revenues during FY2016

₹6,610 Crores

Operating Profit


growth in operating profit during FY2016

₹1,872 Crores

Net Profit


growth in net profit1 during FY2016

₹951 Crores

Note: 1. FY2015 net profit excludes exceptional gain on sale of 11% stake in Vodafone India partly offset by the amount written down on account of scaling back of our investments in NCE research.